EVO301 Meets Primary Endpoint in Phase 2a Study for Moderate-to-Severe Atopic Dermatitis
Evommune reports positive Phase 2a data for EVO301, showing 55% eczema reduction and a safe profile after 12 weeks of treatment.
NOTRELOAD AI
Oscar Health Q4 Results: Loss Widens but Growth and Profitability Plans Remain
Oscar Health reports wider quarterly losses due to higher medical costs, while revenue grows and the company targets profitability in 2026.
CVS Health Misses 2026 Profit Forecast, Shares Drop
CVS Health falls short of Wall Street's 2026 profit expectations despite beating Q4 estimates. Stock drops 3% as company maintains cautious outlook amid healthcare industry challenges.
Spotify Beats Expectations with Record User Growth in Q4 2025
Spotify adds 38M users in Q4 2025, beating forecasts. Stock jumps 10% as new co-CEOs deliver strong earnings, higher margins, and optimistic Q1 outlook despite slowing revenue growth.
Coca-Cola Q4 2025: Revenue Miss Amid Shifting Consumer Trends
Coca-Cola misses Q4 revenue expectations as North American demand weakens. Company projects 4-5% organic growth for 2026 despite headwinds from weight-loss drugs and healthier consumer choices.
TSMC's January Revenue Surges 37% on Booming AI Chip Demand
TSMC reports strong 37% revenue growth in January 2026, exceeding annual targets as AI chip demand drives record capital spending and potential US tariff exemptions.